Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests begin for new poxvirus drug candidate

NCT ID NCT07377175

Summary

This is an early-stage study to check the safety and how the body processes a new drug called BSY001. It involves 76 healthy volunteers who will receive either the drug or a placebo. The main goal is to see how safe different doses are and how long the drug stays in the bloodstream, which is a first step for a potential future treatment for poxvirus infections like monkeypox.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shulan (Hangzhou) Hospital

    RECRUITING

    Hangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.